Nuformix (FRA:1RT) EBITDA Margin %: 0.00% (As of Mar. 2026)


What is Nuformix EBITDA Margin %?

Nuformix FRA:1RT EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Nuformix ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nuformix's EBITDA for the six months ended in Mar. 2026 was €-0.40 Mil. Nuformix's Revenue for the six months ended in Mar. 2026 was €0.00 Mil. Therefore, Nuformix's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Nuformix  (FRA:1RT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nuformix EBITDA Margin % Related Terms

Nuformix EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Nuformix's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix EBITDA Margin % Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -653.95 -2,458.33 0.00 0.00 0.00

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:1RT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Nuformix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuformix EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nuformix's EBITDA Margin % falls into.


Nuformix EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nuformix's EBITDA Margin % for the fiscal year that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-0.728/0
= %

Nuformix's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.4/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Nuformix (FRA:1RT) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nuformix and its competitors. According to the industry distribution chart, Nuformix ranks #999999 out of 945 companies in the Biotechnology industry.
Is Nuformix's EBITDA Margin % too high?
Nuformix's current EBITDA Margin % is 0.00%. Based on the distribution chart, Nuformix ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nuformix's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nuformix ranks #999999 out of 945 companies for EBITDA Margin %. This places Nuformix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nuformix and its competitors. Nuformix's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.